JP2015536949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536949A5 JP2015536949A5 JP2015540824A JP2015540824A JP2015536949A5 JP 2015536949 A5 JP2015536949 A5 JP 2015536949A5 JP 2015540824 A JP2015540824 A JP 2015540824A JP 2015540824 A JP2015540824 A JP 2015540824A JP 2015536949 A5 JP2015536949 A5 JP 2015536949A5
- Authority
- JP
- Japan
- Prior art keywords
- antibiotic
- subject
- administered
- agent
- antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003115 biocidal effect Effects 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 33
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 23
- 239000003242 anti bacterial agent Substances 0.000 claims description 22
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 18
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 claims description 18
- 239000003623 enhancer Substances 0.000 claims description 16
- 239000013011 aqueous formulation Substances 0.000 claims description 12
- 229960001019 oxacillin Drugs 0.000 claims description 12
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 11
- 238000001990 intravenous administration Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- -1 pyrubinium Chemical compound 0.000 claims description 10
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 claims description 9
- 239000004104 Oleandomycin Substances 0.000 claims description 9
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 claims description 9
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims description 9
- 229960003608 clomifene Drugs 0.000 claims description 9
- 229930000755 gossypol Natural products 0.000 claims description 9
- 229950005277 gossypol Drugs 0.000 claims description 9
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 9
- 229960001180 norfloxacin Drugs 0.000 claims description 9
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 claims description 9
- 229960002351 oleandomycin Drugs 0.000 claims description 9
- 235000019367 oleandomycin Nutrition 0.000 claims description 9
- 235000012711 vitamin K3 Nutrition 0.000 claims description 9
- 239000011652 vitamin K3 Substances 0.000 claims description 9
- 229940041603 vitamin k 3 Drugs 0.000 claims description 9
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims description 8
- 239000002132 β-lactam antibiotic Substances 0.000 claims description 8
- 229940124586 β-lactam antibiotics Drugs 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 108010087702 Penicillinase Proteins 0.000 claims description 6
- 229950009506 penicillinase Drugs 0.000 claims description 6
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 206010014665 endocarditis Diseases 0.000 claims description 4
- 238000001361 intraarterial administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 238000007914 intraventricular administration Methods 0.000 claims description 4
- 229960003085 meticillin Drugs 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 206010060968 Arthritis infective Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000792859 Enema Species 0.000 claims description 2
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 206010062255 Soft tissue infection Diseases 0.000 claims description 2
- 206010000269 abscess Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229960003326 cloxacillin Drugs 0.000 claims description 2
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229960001585 dicloxacillin Drugs 0.000 claims description 2
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims description 2
- 230000002183 duodenal effect Effects 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229960004273 floxacillin Drugs 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 238000003304 gavage Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 230000035764 nutrition Effects 0.000 claims description 2
- 229940054534 ophthalmic solution Drugs 0.000 claims description 2
- 239000002997 ophthalmic solution Substances 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims description 2
- 229960001225 rifampicin Drugs 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 206010040872 skin infection Diseases 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000010254 subcutaneous injection Methods 0.000 claims description 2
- 239000007929 subcutaneous injection Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 229940079593 drug Drugs 0.000 claims 14
- 241000894006 Bacteria Species 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721310P | 2012-11-01 | 2012-11-01 | |
| US61/721,310 | 2012-11-01 | ||
| PCT/US2013/068085 WO2014071198A1 (en) | 2012-11-01 | 2013-11-01 | Antibiotic methods and compositions for bacteria infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536949A JP2015536949A (ja) | 2015-12-24 |
| JP2015536949A5 true JP2015536949A5 (https=) | 2016-12-15 |
Family
ID=50628103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540824A Pending JP2015536949A (ja) | 2012-11-01 | 2013-11-01 | 細菌感染症のための抗生物質を用いる方法および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9861619B2 (https=) |
| EP (1) | EP2916653A4 (https=) |
| JP (1) | JP2015536949A (https=) |
| WO (1) | WO2014071198A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516055A (ja) * | 2013-03-15 | 2016-06-02 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 細菌感染症に対する方法及び組成物 |
| CN114794129B (zh) * | 2021-06-21 | 2023-09-26 | 广西壮族自治区亚热带作物研究所（广西亚热带农产品加工研究所） | 一种防治澳洲坚果炭疽病的农药组合物 |
| CN113599398B (zh) * | 2021-09-14 | 2024-01-26 | 中国农业科学院兰州畜牧与兽药研究所 | 一种治疗犊牦牛肠型大肠杆菌病的药物组合物及制备方法 |
| CN114259485A (zh) * | 2021-12-14 | 2022-04-01 | 华中科技大学协和深圳医院 | 苯溴马隆用于抗金黄色葡萄球菌及其生物被膜感染的用途 |
| CN114456189B (zh) * | 2022-02-23 | 2023-03-31 | 安阳工学院 | 一种岩白菜素磺酸酯衍生物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3272701A (en) * | 1962-02-27 | 1966-09-13 | Vineland Lab Inc | Free flowing medicated drinking water for poultry and animals |
| FR2645018B2 (fr) * | 1987-06-02 | 1991-06-14 | Boulay Maurice | Composition destinee a lutter contre les staphilocoques, les champignons et autres parasites |
| US6569830B1 (en) | 1999-03-05 | 2003-05-27 | Ambi, Inc. | Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains |
| US6555569B2 (en) * | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| ITMI20031011A1 (it) * | 2003-05-20 | 2004-11-21 | Vanetta S P A | Composti biocidi per il trattamento delle acque. |
| US20070258996A1 (en) * | 2005-12-23 | 2007-11-08 | The Sterilex Corporation | Antimicrobial compositions |
| US20100234348A1 (en) | 2006-08-04 | 2010-09-16 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
| US20120064125A1 (en) * | 2009-04-17 | 2012-03-15 | Horswill Alexander R | Agr-mediated inhibition of methicillin resistant staphylococcus aureus |
| EP2243482A1 (en) | 2009-04-20 | 2010-10-27 | Polichem SA | Use of nifuratel to treat infections caused by atopobium species |
| GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
| WO2013103780A1 (en) | 2012-01-06 | 2013-07-11 | Trustees Of Boston University | Compositions and methods to boost endogenous ros production from bacteria |
-
2013
- 2013-11-01 EP EP13850898.1A patent/EP2916653A4/en not_active Withdrawn
- 2013-11-01 US US14/439,850 patent/US9861619B2/en active Active
- 2013-11-01 WO PCT/US2013/068085 patent/WO2014071198A1/en not_active Ceased
- 2013-11-01 JP JP2015540824A patent/JP2015536949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2339003T3 (es) | Rifalazil para tratar infecciones por clostridium difficile. | |
| JP2015536949A5 (https=) | ||
| CN101623499A (zh) | 抗生素和匹多莫德的药物组合物及其制备方法和药物应用 | |
| Michalopoulos et al. | Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin | |
| Giguère et al. | Antimicrobial drug use in horses | |
| JP2012082219A (ja) | 感染症の治療 | |
| BRPI0916885B1 (pt) | composição farmacêutica | |
| JP5854987B2 (ja) | 感染症治療用のチオキサンテン誘導体 | |
| ES2367896T3 (es) | Agente para el tratamiento del sindrome del colon irritable con predominio de diarrea. | |
| KR20180051622A (ko) | 항생물질 요법 | |
| KR20110095856A (ko) | 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합 | |
| US20100120896A1 (en) | Once-A-Day RNA-Polymerase inhibiting and elongation factor G (EF-G) inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant staphylococcus aureus | |
| TWI818910B (zh) | 吸入性肺炎、肺化膿症或肺膿瘍之治療劑 | |
| JP2004529095A (ja) | 抗菌性ｉｂ−３６７ペプチドの経口投与による人工呼吸器関連性肺炎の予防法 | |
| Hawks | Antibiotic therapy of staphylococcal infections | |
| Dasgupta et al. | Antimicrobials in Respiratory Medicine | |
| Poissy et al. | New antibiotics for severe ICU-aquired bacterial infections | |
| Pezzani | Cefuroxime | |
| Satish et al. | A REVIEW ON THE USE OF VANCOMYCIN | |
| Gupta et al. | Pediatric tonsillopharyngitis—an evaluation of cefprozil in Indian patients | |
| TW202415375A (zh) | 吸入性肺炎、肺化膿症或肺膿瘍之治療劑 | |
| Jawień et al. | Bacterial meningitis-principles of antimicrobial treatment | |
| AU2014200107B2 (en) | Compositions and methods of treatment comprising ceftaroline | |
| HK40098387A (zh) | 吸入性肺炎、肺化脓或肺脓肿的治疗剂 | |
| Hopkins et al. | Trovafloxacin vs Ciprofloxacin±Clindamycin/Metronidazole in Patients with Nosocomial Pneumonia. |